Related Experiment Video
Updated: Aug 18, 2025
06:08
A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
Published on: March 21, 2025
338
Using PSMA imaging for prognostication in localized and advanced prostate cancer
Matthew J Roberts1,2,3, Tobias Maurer4, Marlon Perera5
1Department of Urology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia. m.roberts2@uq.edu.au.
Nature Reviews. Urology
|December 6, 2022
Summary
Prostate-specific membrane antigen (PSMA) PET imaging shows promise in prostate cancer management. High PSMA expression correlates with survival outcomes, but its sensitivity in detecting all metastases needs further study.
Area of Science:
- Nuclear medicine
- Oncology
- Radiopharmaceuticals
Background:
- Prostate-specific membrane antigen (PSMA)-directed applications are transforming prostate cancer management.
- Rapid clinical adoption of PSMA-PET has outpaced long-term outcome data.
Purpose of the Study:
- To systematically evaluate the prognostic implications of PSMA-PET in prostate cancer.
- To correlate PSMA expression and PET uptake with oncological outcomes.
Main Methods:
- Analysis of existing data correlating PSMA expression (IHC/PET) with prognostic factors and survival.
- Review of treatment outcomes in relation to PSMA-PET findings for localized and recurrent disease.
Main Results:
- High PSMA expression (IHC/PET) is linked to traditional prognostic factors and survival outcomes.
- PSMA-PET has limitations in detecting all metastases, impacting curative treatment success.
- Low PSMA-PET uptake can be favorable, but may indicate poor prognosis with high 18F-FDG uptake in metastatic castration-resistant prostate cancer.
Conclusions:
- PSMA-PET shows prognostic value in prostate cancer, but its sensitivity for detecting all metastases is limited.
- Further clinical trials are essential to validate PSMA-PET's role in guiding prostate cancer management and confirm oncological outcomes.
